Quantcast

Latest Ipilimumab Stories

2013-06-14 23:01:56

Published in the Journal for ImmunoTherapy of Cancer, review offers recommendations for manufacturing, pre-clinical studies, and clinical trial designs of cancer immunotherapies Milwaukee, WI (PRWEB) June 14, 2013 A picture of what the FDA is looking for in cancer immunotherapy product development appears in an extensive review article published in the inaugural issue of the Journal for ImmunoTherapy of Cancer. This review outlines a series of recommendations from the FDA, including cited...

2013-06-03 12:37:18

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO). Several patients...

2013-06-03 12:26:51

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer. The results were presented at the 2013 meeting of the American Society of Clinical Oncology today in Chicago by Dr. Antoni Ribas, professor of medicine in the UCLA division of hematology-oncology, who led the research. Following Ribas' presentation, the...

2013-06-02 23:01:05

A promising, new cancer immunotherapy combination treatment showing long term survival for patients with metastatic melanoma was highlighted today at the American Society of Clinical Oncology Annual Meeting in Chicago. (PRWEB) June 02, 2013 A promising, new cancer immunotherapy combination treatment showing long term survival for patients with metastatic melanoma was highlighted today at the American Society of Clinical Oncology Annual Meeting in Chicago. Results form a phase II study...

2013-06-02 23:00:29

Additional Data Released at ASCO Annual Meeting Shows More Promising Results for Immunotherapy as a Treatment Option in Melanoma Chicago, IL (PRWEB) June 02, 2013 Some of the most promising results ever seen in melanoma clinical trials were announced today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The drugs work by manipulating the immune system to increase anti-tumor immunity. Specifically, they target the program death-1 (PD-1) receptor pathway which...

2013-05-28 23:04:09

Treatment with ipilimumab can result in durable antitumor effects despite a low overall response rate in patients with advanced mucosal melanoma (MM). Richard D. Carvajal, MD, Medical Oncologist at the Memorial Sloan-Kettering Cancer Center in New York, led the multicenter, retrospective study, recently published in The Oncologist, in collaboration with researchers from the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston. Durham, NC (PRWEB) May 28, 2013 Treatment...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related